<DOC>
	<DOCNO>NCT01009424</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacodynamics , pharmacokinetics RO5024118 follow repeat inhalation patient moderate-to-severe Chronic Obstructive Pulmonary Disease ( COPD ) . Patients randomize receive multiple inhaled dos R7103 , compare placebo . The target sample size approximately 30 individual .</brief_summary>
	<brief_title>A Multi-center Study Investigate Safety , Tolerability , Pharmacodynamics Pharmacokinetics R7103 Following Repeated Inhalation Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Male female patient 4070 year age , inclusive . Body Mass Index 1832 kg/m2 , inclusive . Female patient must surgically sterile post menopausal past year confirm negative hormone panel . Male patient partner childbearing potential must use two method contraception , one must barrier method duration study 7 day last dose . Diagnosis moderatetosevere COPD ( GOLD Stage IIIII ) . Current smoker history smoking last three month . Use continuous daily long term oxygen therapy requirement oxygen therapy exercise . History cardiac conduction abnormality ventricular tachyarrhythmias . Exacerbation COPD within 8 week first dose .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>